Loading...

Cleveland BioLabs

DB:7CB1
Snowflake Description

Adequate balance sheet with weak fundamentals.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
7CB1
DB
$17M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Cleveland BioLabs, Inc., a biopharmaceutical company, develops novel approaches to activate the immune system and address various medical needs in the United States and Russia. The last earnings update was 42 days ago. More info.


Add to Portfolio Compare Print
  • Cleveland BioLabs has significant price volatility in the past 3 months.
7CB1 Share Price and Events
7 Day Returns
-6.2%
DB:7CB1
-0.7%
DE Biotechs
2.5%
DE Market
1 Year Returns
-42.5%
DB:7CB1
-9.2%
DE Biotechs
-6.7%
DE Market
7CB1 Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Cleveland BioLabs (7CB1) -6.2% -9.3% 9.8% -42.5% -29.4% -85.3%
DE Biotechs -0.7% 4.7% -6.2% -9.2% 44% 8.7%
DE Market 2.5% 3.3% 9.2% -6.7% 9% 13.5%
1 Year Return vs Industry and Market
  • 7CB1 underperformed the Biotechs industry which returned -9.2% over the past year.
  • 7CB1 underperformed the Market in Germany which returned -6.7% over the past year.
Price Volatility
7CB1
Industry
5yr Volatility vs Market
Related Companies

7CB1 Value

 Is Cleveland BioLabs undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.

In this section, we usually try to help investors determine whether Cleveland BioLabs is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Cleveland BioLabs has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis. You can see them here.

Show me the analysis anyway

INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Cleveland BioLabs. This is due to cash flow or dividend data being unavailable. The share price is €1.351.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Cleveland BioLabs's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Cleveland BioLabs's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:7CB1 PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in USD $-0.32
NasdaqCM:CBLI Share Price ** NasdaqCM (2019-04-18) in USD $1.51
Europe Biotechs Industry PE Ratio Median Figure of 30 Publicly-Listed Biotechs Companies 22.53x
Germany Market PE Ratio Median Figure of 421 Publicly-Listed Companies 19.69x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Cleveland BioLabs.

DB:7CB1 PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqCM:CBLI Share Price ÷ EPS (both in USD)

= 1.51 ÷ -0.32

-4.72x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Cleveland BioLabs is loss making, we can't compare its value to the Europe Biotechs industry average.
  • Cleveland BioLabs is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Cleveland BioLabs's expected growth come at a high price?
Raw Data
DB:7CB1 PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -4.72x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts
Not available
Europe Biotechs Industry PEG Ratio Median Figure of 22 Publicly-Listed Biotechs Companies 1.31x
Germany Market PEG Ratio Median Figure of 270 Publicly-Listed Companies 1.58x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Cleveland BioLabs, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Cleveland BioLabs's assets?
Raw Data
DB:7CB1 PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in USD $-0.13
NasdaqCM:CBLI Share Price * NasdaqCM (2019-04-18) in USD $1.51
Germany Biotechs Industry PB Ratio Median Figure of 15 Publicly-Listed Biotechs Companies 3.85x
Germany Market PB Ratio Median Figure of 570 Publicly-Listed Companies 1.87x
DB:7CB1 PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqCM:CBLI Share Price ÷ Book Value per Share (both in USD)

= 1.51 ÷ -0.13

-11.75x

* Primary Listing of Cleveland BioLabs.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Cleveland BioLabs has negative assets, we can't compare the value of its assets to the DE Biotechs industry average.

Next steps:

  1. Examine Cleveland BioLabs's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
  2. When valuing a company like this, investors focus more on how they perceive the size of the opportunity, the company's ability to deliver and scale, and the strength of the team. While we are not analysing this type of data at the moment, if you don’t know where to start, we recommend reading through Cleveland BioLabs's regulatory filings and announcements.
  3. Show me more potentially undervalued companies in the Biotechs industry
  4. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Value checks
We assess Cleveland BioLabs's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Cleveland BioLabs has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

7CB1 Future Performance

 How is Cleveland BioLabs expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Cleveland BioLabs has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.

Show me the analysis anyway

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
47.4%
Expected Biotechs industry annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Cleveland BioLabs expected to grow at an attractive rate?
  • Unable to compare Cleveland BioLabs's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare Cleveland BioLabs's earnings growth to the Germany market average as no estimate data is available.
  • Unable to compare Cleveland BioLabs's revenue growth to the Germany market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
DB:7CB1 Future Growth Rates Data Sources
Data Point Source Value (per year)
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 47.4%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26.1%
Germany Market Earnings Growth Rate Market Cap Weighted Average 11.7%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:7CB1 Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:7CB1 Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2018-12-31 1 -5 -4
2018-09-30 2 -5 -4
2018-06-30 2 -5 -5
2018-03-31 2 -5 -9
2017-12-31 2 -7 -10
2017-09-30 2 -5 -10
2017-06-30 3 -5 -7
2017-03-31 3 -5 -4
2016-12-31 4 -5 -3
2016-09-30 4 -9 -3
2016-06-30 3 -11 -7
2016-03-31 3 -12 -10

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if Cleveland BioLabs is high growth as no earnings estimate data is available.
  • Unable to determine if Cleveland BioLabs is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:7CB1 Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below

All data from Cleveland BioLabs Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:7CB1 Past Financials Data
Date (Data in USD Millions) EPS *
2018-12-31 -0.32
2018-09-30 -0.39
2018-06-30 -0.40
2018-03-31 -0.82
2017-12-31 -0.87
2017-09-30 -0.88
2017-06-30 -0.67
2017-03-31 -0.33
2016-12-31 -0.24
2016-09-30 -0.26
2016-06-30 -0.66
2016-03-31 -1.07

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Cleveland BioLabs will efficiently use shareholders’ funds in the future without estimates of Return on Equity.

Next steps:

  1. Examine Cleveland BioLabs's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
  2. Cleveland BioLabs's future outlook can be gauged by looking at industry trends and market size, and determining how well-positioned the company is compared to its competitors. Take a look at other high-growth Pharmaceuticals & Biotech companies here
  3. Cleveland BioLabs's competitive advantages and company strategy can generally be found in its financial reports archived here.
  4. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Future performance checks
We assess Cleveland BioLabs's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Cleveland BioLabs has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

7CB1 Past Performance

  How has Cleveland BioLabs performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Cleveland BioLabs's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Cleveland BioLabs does not make a profit even though their year on year earnings growth rate was positive over the past 5 years.
  • Unable to compare Cleveland BioLabs's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Cleveland BioLabs's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Cleveland BioLabs's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Cleveland BioLabs Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:7CB1 Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 1.14 -3.61 2.32
2018-09-30 1.77 -4.35 2.55
2018-06-30 1.79 -4.51 2.41
2018-03-31 1.60 -9.27 2.45
2017-12-31 1.95 -9.71 2.50
2017-09-30 2.07 -9.77 2.61
2017-06-30 2.91 -7.37 2.78
2017-03-31 3.28 -3.65 2.97
2016-12-31 3.52 -2.66 3.38
2016-09-30 3.80 -2.85 4.30
2016-06-30 3.16 -7.11 4.41
2016-03-31 2.91 -9.66 5.23
2015-12-31 2.71 -12.64 5.76
2015-09-30 2.83 0.06 6.19
2015-06-30 2.74 -0.92 7.11
2015-03-31 2.97 -0.44 7.76
2014-12-31 3.70 1.63 8.47
2014-09-30 6.18 -10.01 9.10
2014-06-30 7.40 -10.00 10.20
2014-03-31 8.45 -9.08 10.97
2013-12-31 8.49 -17.26 12.04
2013-09-30 6.78 -13.79 11.53
2013-06-30 5.36 -20.57 11.86
2013-03-31 4.01 -22.61 12.17
2012-12-31 3.57 -18.23 11.12
2012-09-30 3.36 -28.54 11.98
2012-06-30 6.94 -20.35 13.00

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Cleveland BioLabs has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Cleveland BioLabs has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Cleveland BioLabs improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Cleveland BioLabs's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Cleveland BioLabs has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

7CB1 Health

 How is Cleveland BioLabs's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Cleveland BioLabs's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Cleveland BioLabs is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Cleveland BioLabs's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Cleveland BioLabs's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Cleveland BioLabs has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Cleveland BioLabs Company Filings, last reported 3 months ago.

DB:7CB1 Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 3.61 0.00 4.12
2018-09-30 4.10 0.00 5.34
2018-06-30 5.26 0.00 6.53
2018-03-31 6.21 0.00 7.68
2017-12-31 7.41 0.00 8.79
2017-09-30 8.60 0.00 10.06
2017-06-30 9.87 0.00 11.46
2017-03-31 11.25 0.00 13.07
2016-12-31 12.85 0.00 15.25
2016-09-30 14.24 0.00 14.93
2016-06-30 13.09 0.00 16.35
2016-03-31 14.95 0.00 17.98
2015-12-31 15.04 0.00 19.62
2015-09-30 14.53 2.13 22.51
2015-06-30 -5.92 3.97 3.64
2015-03-31 -1.41 4.06 5.03
2014-12-31 1.79 4.15 3.10
2014-09-30 3.32 4.24 9.15
2014-06-30 6.45 4.17 11.10
2014-03-31 3.99 7.69 13.67
2013-12-31 1.58 7.56 10.35
2013-09-30 2.33 7.44 14.62
2013-06-30 6.30 0.13 13.55
2013-03-31 9.93 0.15 21.06
2012-12-31 20.49 0.17 28.29
2012-09-30 6.14 0.19 19.14
2012-06-30 17.39 0.20 22.02
  • Cleveland BioLabs has no debt.
  • Cleveland BioLabs has no debt compared to 5 years ago when it was 470.6%.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Cleveland BioLabs has less than a year of cash runway based on current free cash flow.
  • Cleveland BioLabs has less than a year of cash runway if free cash flow continues to reduce at historical rates of -35.3% each year.
X
Financial health checks
We assess Cleveland BioLabs's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Cleveland BioLabs has a total score of 4/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

7CB1 Dividends

 What is Cleveland BioLabs's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Cleveland BioLabs dividends.
If you bought €2,000 of Cleveland BioLabs shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Cleveland BioLabs's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Cleveland BioLabs's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:7CB1 Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.9%
Germany Market Average Dividend Yield Market Cap Weighted Average of 324 Stocks 3%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.9%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Cleveland BioLabs has not reported any payouts.
  • Unable to verify if Cleveland BioLabs's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Cleveland BioLabs's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Cleveland BioLabs has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Cleveland BioLabs's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.9%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Cleveland BioLabs afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Cleveland BioLabs has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

7CB1 Management

 What is the CEO of Cleveland BioLabs's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Yakov Kogan
COMPENSATION $286,800
AGE 45
TENURE AS CEO 6.8 years
CEO Bio

Dr. Yakov N. Kogan, Ph.D., MBA co-founded Cleveland Biolabs, Inc. in 2000 and has been its Chief Executive Officer since June 14, 2012 and serves as its interim Principal Financial Officer since June 16, 2017 and also serves as its Secretary. Dr. Kogan serves as an Executive Vice President of Business Development and Secretary of Taiwan Indigena Botanica Co., Ltd. (formerly, Mega Biotech & Electronics Co., Ltd.). He served as Interim Chief Executive Officer of Cleveland Biolabs from January 2012 to June 14, 2012 and served as its Chief Operating Officer from February 8, 2008 to January 2012. He served as Secretary of Cleveland Biolabs, Inc., from March 2006 to June 2012 and served as its Executive Vice President of Business Development from June 2003 to February 2008. He served as Vice President of Research and Development and Product Marketing at Digital Fuel Technologies. Prior to co-founding Digital Fuel Technologies in 2000, Dr. Kogan led large development projects for the wireless communications industry at Amdocs. For seven years prior to Amdocs, he managed large-scale development projects for major Israeli banks, including Leumi Bank, Discount Bank and Post Bank. From 2001 to 2004, he served as Director for Business Development at Integrated Genomics, Inc. (Chicago, IL), a world leader in comparative genomics and applied bioinformatics, where he was responsible for commercial sales and expansion of its capital base. Prior to his tenure in business development, Dr. Kogan served as a Group Leader and Senior Scientist at Integrated Genomics, Inc. and ThermoGen, Inc. (Chicago, IL) and as Research Associate at the University of Chicago. Dr. Kogan previously worked at Integrated Genomics where he ran production units, as well as negotiated multi-million-dollar research contracts. He has more than 10 years of experience in biology and biotechnology. He served as a Director of Cleveland Biolabs, Inc. since June 2003. He serves as a Director at Russian Pharmaceutical Company Incuron, LLC and Taiwan Indigena Botanica Co., Ltd. He served as Director of Digital Fuel Technologies, Inc. He has published many research papers on data integration, query languages for XML and DBMS for semi-structured data. He holds a B.S. (cum laude) and M.S. in Computer Science from Hebrew University. Dr. Kogan holds Ph.D. degree in Molecular Biology from All-Union Research Institute of Genetics and Selection of Industrial Microorganisms (VNII Genetica), as well as M.S. in Biology from the Moscow State University. He holds an MBA degree from the University of Chicago Graduate School Of Business.

CEO Compensation
  • Yakov's compensation has been consistent with company performance over the past year.
  • Yakov's remuneration is about average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the Cleveland BioLabs management team in years:

6.8
Average Tenure
62
Average Age
  • The average tenure for the Cleveland BioLabs management team is over 5 years, this suggests they are a seasoned and experienced team.
Management Team

Yakov Kogan

TITLE
CEO, Interim Principal Financial Officer & Secretary
COMPENSATION
$287K
AGE
45
TENURE
6.8 yrs

Langdon Miller

TITLE
President & Chief Medical Officer
COMPENSATION
$120K
AGE
64
TENURE
3.9 yrs

Andrei Gudkov

TITLE
Chief Scientific Officer
COMPENSATION
$111K
AGE
62
TENURE
15.8 yrs

Ann Hards

TITLE
Executive Vice President of Regulatory Affairs
Board of Directors Tenure

Average tenure and age of the Cleveland BioLabs board of directors in years:

2.8
Average Tenure
38
Average Age
  • The average tenure for the Cleveland BioLabs board of directors is less than 3 years, this suggests a new board.
Board of Directors

Lea Verny

TITLE
Chair of the Board
COMPENSATION
$35K
AGE
52
TENURE
2.8 yrs

Randy Saluck

TITLE
Director
COMPENSATION
$35K
AGE
52
TENURE
2.8 yrs

Anna Evdokimova

TITLE
Independent Director
AGE
42
TENURE
3.8 yrs

Ivan Persiyanov

TITLE
Director
AGE
38
TENURE
3.8 yrs

Daniil Talyanskiy

TITLE
Director
AGE
33
TENURE
2.8 yrs

Alexander Andryuschechkin

TITLE
Director
AGE
34
TENURE
2.8 yrs

Ivan Fedyunin

TITLE
Director
AGE
30
TENURE
0.7 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
X
Management checks
We assess Cleveland BioLabs's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Cleveland BioLabs has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

7CB1 News

Simply Wall St News

7CB1 Company Info

Description

Cleveland BioLabs, Inc., a biopharmaceutical company, develops novel approaches to activate the immune system and address various medical needs in the United States and Russia. Its proprietary platform of toll-like immune receptor activators (TLR) has applications in mitigation of radiation injury, radiation oncology, and vaccines. The company’s product candidate is entolimod, an immune-stimulatory agent, which is used as a medical radiation countermeasure and other indications in radiation oncology. It is also developing Mobilan, a recombinant non-replicating adenovirus that directs expression of TLR5 and its agonistic ligand. Cleveland BioLabs, Inc. has strategic partnerships with the Cleveland Clinic, Roswell Park Cancer Institute, and Everon Biosciences. The company was founded in 2003 and is headquartered in Buffalo, New York.

Details
Name: Cleveland BioLabs, Inc.
7CB1
Exchange: DB
Founded: 2003
$14,875,351
11,298,239
Website: http://www.cbiolabs.com
Address: Cleveland BioLabs, Inc.
73 High Street,
Buffalo,
New York, 14203,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqCM CBLI Common Stock Nasdaq Capital Market US USD 21. Jul 2006
DB 7CB1 Common Stock Deutsche Boerse AG DE EUR 21. Jul 2006
Number of employees
Current staff
Staff numbers
14
Cleveland BioLabs employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/18 21:47
End of day share price update: 2019/04/18 00:00
Last earnings filing: 2019/03/07
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.